Abstract

http://ssrn.com/abstract=787224
 
 

Citations (3)



 
 

Footnotes (53)



 


 



Agony in the Antipodes: The Generic Drug Provisions of the Australia-U.S. Free Trade Agreement


Kevin Outterson


Boston University School of Law


Journal of Generic Medicines, Vol. 2, No. 4, pp. 316-326, July 2005

Abstract:     
The Australia-U.S. Free Trade Agreement (AUSFTA), which entered into force on January 1, 2005, contains many remarkable provisions of interest to generic drug companies. The AUSFTA selectively exports U.S. generic drug laws of great import to generic drug manufacturers, and is uniquely intrusive into domestic pharmaceutical and political spheres. The AUSFTA is important both in its own right, and as a model for future U.S. free trade agreement negotiations.

Beyond the generic drug industry, the provisions are of interest to consumers who pay higher prices when generic drug entry is delayed, and stands as an example of the lack of transparency and accountability in the negotiation of free trade agreements.

Number of Pages in PDF File: 14

Keywords: Australia, United States, free trade agreement, AUSFTA, generic, pharmaceutical, Hatch-Waxman, transparency

JEL Classification: F14, I18, K33

Accepted Paper Series


Download This Paper

Date posted: August 24, 2005  

Suggested Citation

Outterson, Kevin, Agony in the Antipodes: The Generic Drug Provisions of the Australia-U.S. Free Trade Agreement. Journal of Generic Medicines, Vol. 2, No. 4, pp. 316-326, July 2005. Available at SSRN: http://ssrn.com/abstract=787224

Contact Information

Kevin Outterson (Contact Author)
Boston University School of Law ( email )
765 Commonwealth Avenue
Boston, MA 02215
United States
Feedback to SSRN


Paper statistics
Abstract Views: 1,147
Downloads: 172
Download Rank: 100,149
Citations:  3
Footnotes:  53

© 2014 Social Science Electronic Publishing, Inc. All Rights Reserved.  FAQ   Terms of Use   Privacy Policy   Copyright   Contact Us
This page was processed by apollo3 in 0.344 seconds